Blue Trust Inc. Purchases 427 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Blue Trust Inc. grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 540.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 506 shares of the biotechnology company’s stock after acquiring an additional 427 shares during the quarter. Blue Trust Inc.’s holdings in Ascendis Pharma A/S were worth $76,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Westfield Capital Management Co. LP raised its stake in Ascendis Pharma A/S by 3.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after buying an additional 267,881 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after buying an additional 155,971 shares during the period. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the third quarter worth approximately $60,000. Finally, ARS Investment Partners LLC grew its position in Ascendis Pharma A/S by 0.9% during the fourth quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock worth $36,549,000 after buying an additional 2,369 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ASND. UBS Group began coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price for the company. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Stifel Nicolaus boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Finally, Wedbush reaffirmed an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and a consensus price target of $191.57.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $120.87 on Friday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The company’s 50 day moving average price is $132.60 and its two-hundred day moving average price is $132.49. The firm has a market capitalization of $7.34 billion, a P/E ratio of -14.96 and a beta of 0.64.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.